Gilead Sciences, Inc.





Market Closed - Nasdaq 21:00:00 18/07/2024 BST 5-day change 1st Jan Change
73.51 USD +0.29% Intraday chart for Gilead Sciences, Inc. +5.06% -9.26%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Gilead Sciences Chief Medical Officer Merdad Parsey to Leave MT
Gilead Sciences Chief Medical Officer to Step Down DJ
Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025 CI
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78 MT
RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating MT
Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93 MT
HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study MT
HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV CI
Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia CI
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117 MT
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer CI
Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80 MT
Tech overload on Wall Street Our Logo
Wall Street set for muted open as investors await business survey data RE
Nvidia Slide Stifles US Equity Futures Pre-Bell MT
Top Premarket Gainers MT
Wall Street futures edge lower ahead of business survey data RE
Equity Markets Close Mixed as Investors Weigh Economic Data MT
Equity Markets Close Mixed After Macro Data MT
Health Care Stocks Rise Behind Gilead -- Health Care Roundup DJ
US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Mixed Thursday Afternoon MT
Equity Markets Mixed as Traders Weigh Macro Data MT
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
73.3 USD
Average target price
83.01 USD
Spread / Average Target
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. News Gilead Sciences, Inc.
  5. Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise